tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Data on CG Oncology’s Cretostimogene Justifies Buy Rating
PremiumRatingsPromising Data on CG Oncology’s Cretostimogene Justifies Buy Rating
29d ago
Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market
Premium
Ratings
Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market
1M ago
CG Oncology announces data from BOND-003 Cohort P, CORE-008 Cohort A
Premium
The Fly
CG Oncology announces data from BOND-003 Cohort P, CORE-008 Cohort A
1M ago
CG Oncology initiated with a Buy at Truist
PremiumThe FlyCG Oncology initiated with a Buy at Truist
1M ago
CG Oncology price target raised to $61 from $53 at RBC Capital
Premium
The Fly
CG Oncology price target raised to $61 from $53 at RBC Capital
2M ago
CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation
Premium
Ratings
CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation
2M ago
CG Oncology’s Promising Advances in NMIBC Treatment Drive Buy Rating with $75 Target
PremiumRatingsCG Oncology’s Promising Advances in NMIBC Treatment Drive Buy Rating with $75 Target
2M ago
Buy Rating Affirmed for CG Oncology: Promising Advancements and Market Potential of Cretostimogene
Premium
Ratings
Buy Rating Affirmed for CG Oncology: Promising Advancements and Market Potential of Cretostimogene
2M ago
CG Oncology price target lowered to $60 from $62 at BofA
Premium
The Fly
CG Oncology price target lowered to $60 from $62 at BofA
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100